

## **Keynote Address: Toward a Treatment for VHL Disease: HIF-2 Inhibitors**

---

### **William G. Kaelin Jr.**

2019 Nobel Laureate in Medicine; Sidney Farber Professor of Medicine, Harvard Medical School; Investigator, Howard Hughes Medical Institute; Dana-Farber Cancer Institute, Boston, MA, USA

Functional inactivation of the VHL tumor suppressor protein (pVHL) causes the inappropriate accumulation of the HIF transcription factor. Dysregulation of HIF, and specifically dysregulation of HIF2, plays an important role in the pathogenesis of tumors linked to pVHL inactivation. PT-2977 (now called MK-6482) has advanced to Phase 3 trials for the treatment of kidney cancers, which are frequently linked to pVHL inactivation, based on promising Phase 2 data. 61 VHL Disease patients with measurable kidney tumors, as well as other incidental tumors, were recently treated with MK-6482 in a Phase 2 trial. Preliminary data strongly suggest that MK-6482 has beneficial effects in this setting.